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Background: Morgana/chp-1 is a chaperone protein regulating ROCK activity 
and it is involved in centrosome duplication and tumorigenesis. Morgana 
+/- mice develop with age a fatal transplantable myeloproliferative disease 
similar to aCML, presenting centrosome amplification as well as cytogenetic 
abnormalities in bone marrow (BM). Notably, low morgana expression levels 
were found in the BM of aCML-affected patients and in a portion of CML 
Philadelphia positive patients. To assess whether morgana gene (CHORDC1) 
mutations can be responsible for low morgana expression levels in aCML 
patients we screened exome sequencing data obtained; no mutation were 
detectable suggesting that more complex regulatory mechanisms are 
involved in Morgana underexpression. 
Aims: The aim of this study was to understand the mechanism responsible 
of Morgana reducted expression in aCML in order to identify a new pathway 
druggable to restore Morgana levels. 
Methods: RNAs extracted from 9 primary aCML bone marrow samples collected 
at diagnosis after informed consent was reverse transcripted in c-DNA 
using random examers. The amplification products derived from Morgana 
gene were purified using Gel Extraction System and sequenced with ABI 
Prism 3100 Capillary Genetic Analyzer (Applied Biosystems). To evaluate 
the amount of the wild type and alternative transcript, we used two specific 
TAQMAN probes, one able to recognise only the wild type form and one 
other able to recognise both the transcripts. Protein analysis were performed 
by immunohistochemistry (IHC) experiments on formalin-fixed, paraffinembedded 
bone marrows. Exome sequencing was used to extend to a larger 
portion of aCML patients and to analyze another pathology (AML) in order to 
verify the specificity of this inactivation. 
Results: In addition to the main Morgana mRNA we found the co-existence 
of another transcript; direct sequencing of amplification products confirmed 
the presence of an alternative transcript (AS) which lacks the entire exon 3 
of Morgana; this phenomenon produces a change on the correct reading 
frame and as consequence after 9 nucleotide the generation an earlier STOP 
codon. The product of this new transcript isn’t a functional protein. Next we 
decide to quantify this alternative transcript by using one probe able to recognize 
both the transcripts and one probe spanning the exons 4 and 5 of 
Morgana and so able to recognize only the wild type form. We observed that 
unlike the group of healthy donors all the aCML where Morgana wild type is 
low have an high presence of alternative transcript. Surprisingly in the little 
percentage of aCML with normal Morgana level the alternative splicing is not 
significantly expressed. The generation of this AS colud be the mechanism 
responsible of Morgana down-expression in aCML; in fact all the patients 
with high alternative trascript shown very low level in Morgana protein, 
analysed by IHC. All these data where confirmed by exome sequencing, 
where the alternative transcript is observed on a large portion of aCML while 
in 10 AML tested it is not detectable, suggesting the specificity of this type of 
regulation in this myeloproliferative neoplasm 
Summary and Conclusions: In this preliminary work, we identify one Morgana 
AS responsible of aCML reduced Morgana expression. This could be 
a consequence of mutations of those genes that are involved in the regulation 
of the spliceosome even in the absence of spliceosome gene mutations, 
alternative splicing of specific genes has also been reported with important 
biological consequences and potential therapeutic opportunity. 
